InnoScan 1100 microarray scanner: new publication

Microarray-Based cfDNA Methylation Lung Cancer

An international immunology team built a novel non-sequencing epigenetic chip platform for lung cancer screening, fully dependent on InnoScan 1100 scanner for array fluorescence readout. Researchers extracted cfDNA from patient plasma and implemented a chemoenzymatic labeling strategy to imprint fluorophores only on native methylated CpG sites. Labeled nucleic acids were hybridized to commercial Agilent CGH arrays, then scanned uniformly on InnoScan 1100. Mapix software processed scanner raw signals to generate genome-wide methylation intensity profiles, which distinguished lung adenocarcinoma and squamous cell carcinoma besides separating cancer patients from healthy controls. Data captured by InnoScan supported blind cohort validation with high sensitivity and specificity, and successfully tracked tumor regression or progression after immunochemotherapy. This InnoScan-supported platform eliminates expensive deep sequencing procedures, reducing single-test cost to around 60 US dollars. It provides a convenient liquid biopsy supplement to LDCT imaging, advancing affordable, large-scale population lung cancer molecular screening.

Original article: Sequencing-free On-chip detection of lung cancer by fluorescent enzymatic profiling of cfDNA methylation

Keywords:  

• cfDNA methylation
• liquid biopsy
• lung cancer microarray detection
• InnoScan 1100 scanner
• Mapix
• sequencing-free epigenetic assay
• Microarray-Based cfDNA Methylation Lung Cancer